Physician profile

Andrew C Hsu

Physical Medicine & Rehabilitation · Reno, NV

NPI 1881910255

$7,218.02

in general payments reported to CMS, 2019-2025

34 companies · $605 in 2025

The $605 reported for 2025 was more than what 82% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).

See the full distribution for Physical Medicine & Rehabilitation

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,791.83

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Nevro Corp. $2,266.89 2019-2024 Senza
Medtronic USA, INC. $1,817.09 2019-2020
Nalu Medical, INC. $702.92 2021-2025 Nalu Neurostimulation System
Abbott Laboratories $285.43 2020-2025 Eterna, Proclaim
Amgen INC. $284.38 2019-2022
Abbvie INC. $282.59 2021-2023
Spr Therapeutics, INC $207.19 2023 Sprint Pns System
Collegium Pharmaceutical, INC. $137.17 2019-2025 Xtampza
Globus Medical, INC. $135.70 2025 Senza, Vyrsa V1
Stimwave Technologies Incorporated $121.75 2020
Pfizer INC. $116.05 2019-2025
Vertex Pharmaceuticals Incorporated $100.61 2025
Foundation Fusion Solutions, LLC $97.00 2025
Radius Health, INC. $86.52 2020
Biotissue Holdings INC. $80.04 2019
Show all 33 companies
CompanyGeneral paymentsYearsTop products
Almatica Pharma LLC $63.15 2021
Medtronic, INC. $51.35 2021
Daiichi Sankyo INC. $45.12 2019
Kowa Pharmaceuticals America, INC. $42.14 2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $38.20 2019
Bioventus LLC $28.97 2019
Pacira Pharmaceuticals Incorporated $27.67 2025 Zilretta
Biohaven Pharmaceutical Holding Company LTD. $26.88 2022
Biogen, INC. $22.87 2025 Tysabri, Vumerity
Depuy Synthes Sales INC. $22.73 2025 Monovisc
Scilex Pharmaceuticals INC. $20.74 2024
Stryker Corporation $19.99 2019
Genentech USA, INC. $16.00 2023 Enspryng, Ocrevus
Lilly USA, LLC $15.82 2021
Assertio Therapeutics, INC. $15.12 2020
Boston Scientific Corporation $14.92 2020
Arbor Pharmaceuticals, INC. $14.28 2021
Forte Bio-Pharma LLC $10.74 2021

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$16.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Andrew C Hsu

$7,218.02

in general payments reported 2019-2025

Years
2019-2025
Top company
Nevro Corp.
Context
The $605 reported for 2025 was more than what 82% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).

https://glasscript.com/doctor/312968/andrew-c-hsu

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.